Wyniki wyszukiwania:

Component-based software development regards software construction in terms of conventional engineering disciplines where the assembly of systems from readily-available prefabricated parts is the norm. Because both component-based systems themselves and the stakeholders in component-based development projects are different from traditional software systems, component-based testing also needs to deviate from traditional software testing approaches.

Gross first describes the specific challenges related to component-based testing like the lack of internal knowledge of a component or...

Component-based software development regards software construction in terms of conventional engineering disciplines where the assembly of systems from readily-available prefabricated parts is the norm. Because both component-based systems themselves and the stakeholders in component-based development projects are different from traditional software systems, component-based testing also needs to deviate from traditional software testing approaches.

Gross first describes the specific challenges related to component-based testing like the lack of internal knowledge of a component or...

Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac...

Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac...